The loss of cellular ion homeostasis has been proven to promote NLRP3 inflammasome activation and cell pyroptosis during SARS-CoV-2 infection, thus ion-channel inhibitors (such as Amantadine, Memantine,195 Rimantadine,196 Tretinoin197) could be utilized in treatment with COVID-19 patients. The gene discussed is NLRP3; the disease is COVID-19.